How Pharmacist-Led Remote Prescribing Is Being Used in Primary Care

The share of clinical pharmacists holding independent prescribing qualifications has risen sharply over the past three years, and much of the resulting activity now happens without the pharmacist and patient being in the same room. Pharmacist-led remote prescribing has become one of the most operationally significant elements of a modern primary care pharmacy service, delivering routine prescribing decisions across long-term condition management, medicines optimisation and post-discharge care through telephone and video consultations.

The practical patterns of that work have settled into a recognisable shape across PCNs. Which prescribing decisions are made remotely, which need a face-to-face review, and how the network supervises the pharmacist’s clinical work at distance all determine whether the service delivers the efficiency benefits the model promises.

Key takeaways

  • Independent prescribing has become a recruitment priority for PCN clinical pharmacist posts, with around two-thirds of pharmacists delivering SMRs now holding prescribing qualifications.
  • Long-term condition reviews, titration decisions, repeat prescribing authorisation and deprescribing work make up the bulk of routine pharmacist-led remote prescribing.
  • Independent-prescribing pharmacists prescribe within a defined scope of practice agreed with the network and supported by named clinical supervision.
  • Face-to-face review remains preferred for care home residents, complex polypharmacy in frail patients and any case where the clinical picture is unclear.
  • Written escalation routes and consistent documentation are the operational features that separate reliable services from ad hoc ones.

What pharmacist-led remote prescribing covers

Pharmacist-led remote prescribing refers to any prescribing decision made by a pharmacist working under an independent or supplementary prescribing qualification, without the pharmacist and patient being in the same room. In primary care that typically means telephone or video consultations for routine medicines-related work, along with prescribing decisions made in response to an online consultation or as part of a structured medication review conducted at distance.

The General Pharmaceutical Council sets the professional standards and scope for prescribing pharmacists, and every pharmacist prescribing under those standards works within an agreed personal formulary or defined scope of practice that reflects their training and competence.

Types of prescribing being handled remotely

Long-term condition reviews and dose titration

Hypertension, hyperlipidaemia and type 2 diabetes account for a significant share of pharmacist-led remote prescribing activity in primary care. A pharmacist reviewing a patient by phone or video can assess symptom control, check monitoring results, adjust antihypertensive or lipid-lowering doses within their prescribing scope, and issue the amended prescription within the same consultation. Inhaler therapy for asthma and COPD also translates well, provided the pharmacist has recent evidence of correct inhaler technique.

Repeat prescribing authorisation and deprescribing

Much of the day-to-day repeat prescribing workload authorised by pharmacists happens remotely. Where a prescribing pharmacist is reviewing a patient’s regimen against monitoring results and clinical need, the deprescribing decision that follows can be actioned in the same movement rather than handed back to a GP for signature. That single-consultation completion is one of the largest efficiency gains pharmacist-led remote prescribing delivers.

Scope of practice under independent prescribing

An independent-prescribing pharmacist can prescribe any licensed medicine within their competence, which sounds broad but in practice is constrained by the personal formulary or scope of practice agreed with the network. Most networks define scope explicitly around the conditions the pharmacist is expected to manage:

  • Common long-term conditions with clear treatment protocols, including hypertension, hyperlipidaemia, atrial fibrillation and type 2 diabetes.
  • Medicines optimisation and deprescribing work across polypharmacy patients.
  • Post-discharge medicines reconciliation and adjustment.
  • Named exclusions where prescribing decisions stay with a GP, including controlled drugs, complex mental health prescribing and paediatric prescribing outside specific pathways.

Safety and governance arrangements

Governance for pharmacist-led remote prescribing looks different from equivalent GP-led remote work in one important respect: the supervision structure is explicit. Every prescribing pharmacist working in a PCN has a named clinical supervisor, and the arrangements for reviewing complex or borderline cases are usually documented rather than inferred.

The Royal Pharmaceutical Society publishes prescribing competency standards that networks reference when defining what a prescribing pharmacist is expected to demonstrate. Consistent documentation of each remote consultation, a defined escalation pathway when a case exceeds pharmacist scope, and periodic audit of prescribing decisions form the operational spine of a well-governed service.

Cases still requiring face-to-face review

Not every prescribing decision translates to remote delivery. Care home reviews, complex polypharmacy in frail patients, cases where the clinical picture is unclear from history alone and any situation where a physical examination materially influences the decision continue to require in-person contact. Networks that build those exceptions into the model at the start, rather than discovering them under pressure, protect the reliability of the remote work that does happen.

The BMJ Open 2025 national survey of pharmacists delivering SMRs confirmed that most reviews now happen by phone, with the exception of care home rounds, which continue to require face-to-face contact and significantly more clinical time per patient.

Reviewing how a network deploys its prescribing pharmacists

The value of pharmacist-led remote prescribing depends on scope being defined clearly, supervision being explicit and the boundary with face-to-face work being agreed rather than assumed. Networks that treat that combination as a single service to be designed tend to sustain the efficiency benefits, while those that layer remote prescribing on top of existing GP workflows without clear delineation tend to see the boundary erode.

Working with an experienced provider can help set the pharmacist prescribing scope, agree the supervision structure and match remote and face-to-face activity to the clinical work each best supports, rather than letting the pattern settle by accident.